Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Metaplastic breast cancer Indication Strategy Report 2026: EGFR, Trials and Deals
23 July 2026
2026 Metaplastic breast cancer strategy: epidemiology, EGFR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Male breast cancer Indication Strategy Report 2026: ERα, Trials and Deals
23 July 2026
2026 Male breast cancer strategy: epidemiology, ERα biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Inflammatory breast cancer Indication Strategy Report 2026: HER2, Trials and Deals
23 July 2026
2026 Inflammatory breast cancer strategy: epidemiology, HER2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Neuroendocrine prostate cancer Indication Strategy Report 2026: DLL3, Trials and Deals
23 July 2026
2026 Neuroendocrine prostate cancer strategy: epidemiology, DLL3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Metastatic hormone-sensitive prostate cancer Indication Strategy Report 2026: AR, Trials and Deals
23 July 2026
2026 Metastatic hormone-sensitive prostate cancer strategy: epidemiology, AR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Castration-resistant prostate cancer Indication Strategy Report 2026: PSMA, Trials and Deals
23 July 2026
2026 Castration-resistant prostate cancer strategy: epidemiology, PSMA biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Non-muscle-invasive bladder cancer Indication Strategy Report 2026: IL-15, Trials and Deals
23 July 2026
2026 Non-muscle-invasive bladder cancer strategy: epidemiology, IL-15 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Upper tract urothelial carcinoma Indication Strategy Report 2026: FGFR3, Trials and Deals
23 July 2026
2026 Upper tract urothelial carcinoma strategy: epidemiology, FGFR3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Small cell bladder cancer Indication Strategy Report 2026: DLL3, Trials and Deals
23 July 2026
2026 Small cell bladder cancer strategy: epidemiology, DLL3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
MET exon 14 skipping non-small cell lung cancer Indication Strategy Report 2026: c-Met, Trials and Deals
23 July 2026
2026 MET exon 14 skipping non-small cell lung cancer strategy: epidemiology, c-Met biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
RET fusion-positive non-small cell lung cancer Indication Strategy Report 2026: RET, Trials and Deals
23 July 2026
2026 RET fusion-positive non-small cell lung cancer strategy: epidemiology, RET biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
ALK-positive non-small cell lung cancer Indication Strategy Report 2026: ALK, Trials and Deals
23 July 2026
2026 ALK-positive non-small cell lung cancer strategy: epidemiology, ALK biology, clinical competition, recent deals, unmet need and market attractiveness.